RPRX
Royalty Pharma plcPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 30 Contract: Royalty Pharma Announces R&D Funding Collaboration for Chr…
- Apr 17 Dividend: Royalty Pharma Declares Second Quarter 2026 Dividend
- May 6 ▲ Royalty Pharma reported Q1 2026 Portfolio Receipts of $925M (+10% Yo…
- May 14 to May 26 ▼ 3 days of insider sells: $5.1M by 3 insiders, avg $53.64
- Jun 23 to Jul 1 ▼ 4 days of insider sells: $16.5M by 2 insiders, avg $55.38
- Jun 30 ▲ 3 funds open new positions (13F)
- Aug 5 ▲ Royalty Pharma reported Q2 2026 results with Portfolio Receipts of $…
- Aug 13 to Aug 18 ▼ 2 days of insider sells: $6.6M by 2 insiders, avg $59.84
- Sep 4 FDA: Royalty Pharma announces update on Novartis’ Phase 3 topli…
- Sep 22 to Oct 5 ▼ 3 days of insider sells: $6.3M by 2 insiders, avg $58.45
- Nov 4 ▲ Royalty Pharma reported Q3 2026 Portfolio Receipts of $890M (+9% YoY…
- Nov 4 ▲ Earnings: RPRX Q3 2026 Earnings: EPS $1.21 (+0.4% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
4 insiders sold $34.6M.
- InstitutionsBULLISH
Q2 2026: 54 added (3 new), 25 trimmed or exited. Largest new: Barrow Hanley Mewhinney & Strauss $15.0M, Panagora Asset Management $13.5M.
- AnalystsBULLISH
13 of 14 rate it Buy or better. Median target $74.00 (+8%).
- Short sellersSTEADY
Short interest +1.8% to 13.08M shares. 4.0 days to cover, ≈2.3% of shares.
- TrendUPTREND
11% above its 50-day average. New closing high $70.01 on Nov 11.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | DOUBLED | $627.6M |
| BAILLIE GIFFORD & CO | TRIM | $561.6M |
| NORGES BANK | ADD | $299.2M |
| UBS Group AG | ADD | $176.2M |
| NORDEA INVESTMENT MANAGEMENT AB | DOUBLED | $146.2M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | TRIM | $140.2M |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | $108.5M |
| CITADEL ADVISORS LLC | TRIM | $76.0M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
14 analystsPrice is inside the target range. Median implies +8%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 5, 2026 | Citigroup MAINTAIN | Buy |
| Oct 7, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Sep 8, 2026 | TD Cowen MAINTAIN | Buy |
| Aug 7, 2026 | JP Morgan MAINTAIN | Overweight |
| Jul 13, 2026 | TD Cowen MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Urist Marshall EVP, Research & Investments Nov 6, 2026 | CONVERT | 150,000 sh |
Coyne Terrance P. EVP & CFO Nov 6, 2026 | CONVERT | 150,000 sh |
Coyne Terrance P. EVP & CFO Nov 6, 2026 | CONVERT | 15,000 sh |
Urist Marshall EVP, Research & Investments Nov 6, 2026 | CONVERT | 15,000 sh |
Coyne Terrance P. EVP & CFO Nov 6, 2026 | CONVERT | 100,000 sh |
Coyne Terrance P. EVP & CFO Nov 6, 2026 | CONVERT | 10,000 sh |
Legorreta Pablo G. CEO, Chairman of the Board Nov 4, 2026 | AWARD | 42,209 sh |
Urist Marshall EVP, Research & Investments Nov 4, 2026 | AWARD | 5,341 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | $1.45 | $1.30–$1.59 | +12.0% | $0.00 |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
17 filings · 5 press releases · 3 bullish · 1 bearish · 13 neutral- NEUTRAL SC 13G/ANov 5, 2026
FMR LLC (Fidelity) filed an amended Schedule 13G disclosing a 4.3% passive stake in Royalty Pharma…
Fidelity's reduction below 5% removes any filing obligation to report further decreases, so the next public update may only come with the next 13F filing. Monitor for any conversion to a 13D if…
- NEUTRAL 8-KNov 4, 2026
Royalty Pharma reported Q3 2026 Portfolio Receipts of $890M (+9% YoY) and raised full-year 2026…
The raised guidance and 9% top-line growth are positive, but the $150M impairment and activist context warrant monitoring. Watch for further activist demands and any impact on capital deployment…
- BULLISH PRESS-RELEASENov 4, 2026
Royalty Pharma reported Q3 2026 Portfolio Receipts of $890M (+9% YoY) and Royalty Receipts of…
The raised guidance and continued strong royalty receipts growth (9% YoY) support the company's ability to generate cash for further acquisitions. Monitor upcoming deal announcements and the impact…
- BEARISH CLUSTERSep 30, 2026
Two Royalty Pharma executives sold a combined $5.86M in open-market sales over a one-week window…
Monitor next quarterly filing for any guidance revision or operational update that could explain the selling. The cluster is notable in dollar terms but plan-driven, so the bearish signal is tempered.
All RPRX filing & press-release reports (22)
- SC 13G/A reportNov 5, 2026
- 8-K reportNov 4, 2026
- PRESS-RELEASE reportNov 4, 2026
- CLUSTER reportSep 30, 2026
- PRESS-RELEASE reportSep 4, 2026
- CLUSTER reportAug 19, 2026
- 144 reportAug 12, 2026
- 8-K reportAug 5, 2026
- CLUSTER reportJul 2, 2026
- CLUSTER reportJul 2, 2026
- CLUSTER reportMay 28, 2026
- 8-K reportMay 28, 2026
- CLUSTER reportMay 21, 2026
- CLUSTER reportMay 15, 2026
- 144 reportMay 14, 2026
- 8-K reportMay 6, 2026
- PRESS-RELEASE reportApr 17, 2026
- PRESS-RELEASE reportApr 15, 2026
- DEFA14A reportApr 10, 2026
- PRESS-RELEASE reportMar 30, 2026
- PRESS-RELEASE reportMar 2, 2026
- PRESS-RELEASE reportMar 2, 2026